Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

In partnership with CEL-SCI Corporation, Northeast Ohio Medical University (NEOMED) has produced a new investigational breast cancer vaccine. In animal tests the J-HER vaccine has shown reduction of HER-2/neu expressing breast cancer tumors, reduction mass, absence of tumor in lymph nodes or peritoneal membranes, and changes in angiogenesis.

Dr. Rosenthal, Sarah Stone and Robin Edmonds from NEOMED worked with CEL-SCI’s Dr. Daniel Zimmerman to design and test the LEAPS (Ligand Epitope Antigen Presentation System) technology vaccine. 

Present in most human breast tumor cells, the HER-2/neu protein is the target for different types of immunotherapy with sales of many billions of dollars.  Blocking this receptor protein with an antibody causes the tumor cells to commit suicide, or apoptosis. The J-HER vaccine activates a T lymphocyte response targeted to this protein that promotes killing and control of the tumor cell. In these studies, mice were immunized with the vaccine before, or one week after implantation of HER-2/neu breast cancer cells. In both cases the immune response initiated by the immunization significantly blocked further development and progression of tumors in most of the animals.

More details on the vaccine and technology available here.

NEOMED is located in Rootstown, Ohio. CEL-SCI has operations in Vienna, Virginia, and Baltimore, Maryland.

Recent Posts

Blog Post Archive

Blog Post Categories

Search the Blog

Newsticker


BioOhio Member Mark BioOhio Member

STERIS Corporation buys U.S. Pipe building to expand in Birmingham, AL | WBRC6 Birmingham AL, August 20, 2014

Case Western Reserve University hosts cancer stem cell conference | WKSU Kent University, August 20, 2014

Sinus infection test invented by Ohio State University and Nationwide Children’s Hospital could curb antibiotic overuse | Columbus Business First, August 20, 2014

HealthSpot and CareSource team to improve access to healthcare | BusinessWire, August 20, 2014

EnvisionRxOptions named to Inc. Magazine’s The Inc. 500|5000″ list of America’s fastest-growing companies for second consecutive year | Herald Online, August 20, 2014

Forty attorneys from member firm McNees Wallace & Nurick recognized as Best Lawyers in America | McNees Wallace & Nurick, August 19, 2014

Minimally Invasive Devices and Mitsubishi Medical Japan forge exclusive distribution agreement | PR Newswire, August 19, 2014

Summa Health System President and CEO Thomas Strauss will retire at end of 2014 | Crains Cleveland, August 19, 2014

New device at Ohio State Wexner Medical Center takes aim at cluster headaches | WBNS 10TV Columbus, August 18, 2014

BioOhio Blog: OffWhite reflects on the BioOhio Expo, education is the best kind of marketing | BioOhio, August 15, 2014

$2.71M allocated to improve colleges and universities around Ohio | Cleveland.com, August 15, 2014

ChanTest announces a global campaign to share new findings and developments in cystic fibrosis research | PR Web, August 14, 2014

Cleveland Clinic cancer center gets thumbs-up from city design review committee | The Plain Dealer, August 14, 2014

Cleveland Clinic Chief of Staff Dr. Joseph Hahn to retire after nearly four decades as a neurosurgeon, leader and innovator | The Plain Dealer, August 14, 2014

Senator Rob Portman visits Assurex Health to learn about tests to help veterans struggling with post-traumatic stress disorders and other mental illnesses | Cincinnati.com, August 13, 2014

Collaboration between Miami Valley Hospital and Dayton Children’s Hospital to provide care for high-risk pregnancies and at-risk newborns | PR Web, August 13, 2014

Bacterial Robotics building bactobots engineered to destroy skull-based tumors | MedCity News, August 12, 2014

Lindsey Burns, Clincial Development Associate at Assurex Health, named a 2014 Professional Woman of the Year by the National Association of Professional Women | PR Web, August 12, 2014

Juventas Therapeutics completes enrollment of Phase I/II RETRO-HF trial and demonstrates safety for retrograde infusion of JVS-100 in patients with heart failure | PR Newswire, August 12, 2014

Trends driving Cincinnati’s health care building boom | Cincinnati.com, August 12, 2014